TCM Advisors LLC Invests $705,000 in AbbVie Inc. $ABBV

TCM Advisors LLC bought a new stake in AbbVie Inc. (NYSE:ABBV) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,800 shares of the company’s stock, valued at approximately $705,000.

A number of other hedge funds have also recently modified their holdings of ABBV. FF Advisors LLC increased its position in shares of AbbVie by 3.6% during the second quarter. FF Advisors LLC now owns 1,539 shares of the company’s stock worth $286,000 after purchasing an additional 53 shares in the last quarter. Landaas & Co. WI ADV boosted its position in shares of AbbVie by 1.1% in the 2nd quarter. Landaas & Co. WI ADV now owns 4,955 shares of the company’s stock valued at $920,000 after purchasing an additional 53 shares during the period. Bernardo Wealth Planning LLC grew its stake in AbbVie by 2.9% during the 2nd quarter. Bernardo Wealth Planning LLC now owns 1,909 shares of the company’s stock worth $354,000 after buying an additional 53 shares during the last quarter. LifeSteps Financial Inc. grew its stake in AbbVie by 0.7% during the 2nd quarter. LifeSteps Financial Inc. now owns 7,358 shares of the company’s stock worth $1,366,000 after buying an additional 54 shares during the last quarter. Finally, Silicon Valley Capital Partners increased its position in AbbVie by 10.8% during the first quarter. Silicon Valley Capital Partners now owns 573 shares of the company’s stock worth $118,000 after buying an additional 56 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Down 0.7%

ABBV stock opened at $228.68 on Friday. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. The company’s 50-day moving average price is $228.19 and its 200 day moving average price is $207.90. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The company has a market cap of $404.17 billion, a P/E ratio of 173.24, a P/E/G ratio of 1.24 and a beta of 0.36.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same period in the previous year, the firm posted $3.00 earnings per share. AbbVie’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s payout ratio is presently 496.97%.

Analyst Ratings Changes

ABBV has been the subject of several research reports. HSBC set a $225.00 price target on shares of AbbVie in a research report on Thursday, October 2nd. Piper Sandler restated an “overweight” rating and issued a $289.00 price objective (up from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Erste Group Bank cut shares of AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Evercore ISI raised their price target on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a report on Monday, September 22nd. Finally, Raymond James Financial set a $256.00 price target on AbbVie in a research report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $241.85.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.